Natera, Inc. (NASDAQ:NTRA) Director Sells $563,120.00 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at approximately $1,366,129.12. This represents a 29.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Gail Boxer Marcus also recently made the following trade(s):

• On Wednesday, March 12th, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00.

Natera Trading Down 3.5 %

Shares of NASDAQ NTRA opened at $133.87 on Friday. The company’s 50 day simple moving average is $156.81 and its 200 day simple moving average is $151.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The firm has a market capitalization of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. On average, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. LRI Investments LLC acquired a new stake in shares of Natera in the 4th quarter valued at approximately $29,000. Blue Trust Inc. increased its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc increased its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the period. Finally, Principal Securities Inc. boosted its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NTRA. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 target price on the stock. Sanford C. Bernstein upped their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. Guggenheim raised their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Finally, Piper Sandler upped their target price on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.